Recent thyme emigrants mitigate viral pulmonary pneumonia
Ended Project Grant Awarded Last action
- Award ID
- R21AI185795
- Recipient
-
The Administrators Of Tulane Educational Fund UEI XNY5ULPU8EN6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,058,871
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Place of performance
- New Orleans, LA 70112, USA
Award details come from USAspending.gov.
Description
- Abstract
- Despite 100 years and countless scientific advances since the devastating flu pandemic of 1918, viral respiratory illnesses remain a great pandemic threat. The current covid- 19 outbreak has only emphasized our inability to deal with these deadly viruses. A major shortcoming in treatment is the inability to reduce the massive and life-threatening pulmonary inflammation and injury caused by infection. As we work to develop therapeutic approaches, our lab has turned to the one population that is consistently protected from severe viral pneumonias: children. We postulate that by identifying the mechanisms behind this youthful privilege, we can develop novel therapies to reduce the deadly pneumonia that occurs during severe fatal infection. While just as likely to become infected during viral pandemics, children (ages 4-18) do not typically undergo the severe pulmonary inflammation or mortality that can occur in adults. We are able to recapitulate this protection in prepubescent mice (P23-27) during fatal pandemic flu infection. Our preliminary data show that young mice are less susceptible to mortality and do not undergo the severe pneumonia that is common during severe infection. Moreover, we have discovered that prepubescent mice have sustained output of newly produced CD4+ recent thymic emigrants (rtes) which migrate to the lung during infection. IT has been commonly thought that these cells are unimportant during infection as they are phenotypically "immature", yet our preliminary data show that thymectomy and removal of rtes prior to infection leads to exuberant pulmonary inflammation and increased mortality. Further, tracheal instillation of CD4+rtes during infection reduces pulmonary inflammation, suggesting these cells have ANT-inflammatory properties. Taken together, these data lead US to our central hypothesis that sustained output of anti-inflammatory CD4+ rtes reduces influenza induced pulmonary inflammation. The overall objectives of this exploratory R21 application is to, for the first time, demonstrate the importance of CD4 rtes in an infectious inflammatory setting and to identify how they reduce inflammation. The rationale for this proposed work is that IT will allow for the identification of potential cellular and immune therapies that can be used to reduce life threatening inflammation.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$4,479 | |
| Amendment | $191,250 | |
| Amendment | $22,950 | |
| Amendment | $22,950 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $206,550 | |
| Amendment | $206,550 | |
| Amendment | $206,550 | |
| Original award | $206,550 |
Show all 11
Quick answers
Who received award R21AI185795?
R21AI185795 was awarded to The Administrators Of Tulane Educational Fund by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 23, 2024.
How much is award R21AI185795 worth?
$1,058,871 has been obligated on R21AI185795.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award